To further examine the clinical implications of the FTO-m6A axis in patients, we obtained peripheral blood mononuclear cells (PBMCs) from 14 AML patients, who received 300 mg nilotinib twice daily on days 4–14 after induction and consolidation chemotherapy. This evidence concerns the gene FTO and acute myeloid leukemia.